Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

(HealthDay News) — Acetylsalicylic acid (ASA) hyporesponsiveness after coronary artery bypass graft (CABG) surgery can be overcome by multiple dosing, according to a study published online March 7 in ...

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows ...

Protagenic Therapeutics (PTIX) reported topline safety results from its Phase 1 Multiple Dose study of PT00114. PT00114 is a synthetic analogue of ...

FLORHAM PARK, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...

(HealthDay News) — Bevacizumab is safe and stable when stored at 4 degrees Celsius, even with multiple dosing from a single vial, according to a study published in the July issue of Clinical & ...

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and ...

A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS ...

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible ...

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent ...

The MarketWatch News Department was not involved in the creation of this content. Inmagene Announces Positive Topline Results of a Multiple Ascending Dose (MAD) Study of IMG-004, a Non-covalent ...